Actuate Therapeutics, Inc. (ACTU) stock forecast and price target
Price $0.29 · data as of November 13, 2026
12-month price target
Average target$11.68
Upside / downside+3995.1%
Analysts3
ConsensusNone
Low $8.00Average $11.68High $15.05
Gold marker: average target · white marker: today’s price ($0.29)
Analyst ratings
Strong buy 0Buy 3Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.73 | +31.4% | $0 |
| Next fiscal year ends December 31, 2027 | $-0.66 | +8.7% | $0 |
| Next quarter ends December 31, 2026 | $-0.17 | +5.6% | $0 |
| Quarter after ends March 31, 2027 | $-0.17 | +29.2% | $0 |
Consensus of the analysts covering Actuate Therapeutics, updated daily. In the last 30 days 1 estimates were raised and 1 lowered.
Frequently asked questions
What is the Actuate Therapeutics stock price target?
The average 12-month target from 3 analysts is $11.68, 3995.1% above the current price of $0.29 Targets range from $8.00 to $15.05.
Is Actuate Therapeutics a buy according to analysts?
The consensus rating is “None” (3 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Actuate Therapeutics expected to earn?
Analysts expect EPS of $-0.73 for the fiscal year ending December 31, 2026 and $-0.66 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.